Canada - English - Health Canada

pfizer canada ulc - clindamycin (clindamycin hydrochloride) - capsule - 300mg - clindamycin (clindamycin hydrochloride) 300mg - lincomycins

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - clindamycin hydrochloride - oral capsule - 150mg

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmacia ireland - clindamycin hydrochloride - capsules hard - 150 base milligrams

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - clindamycin hydrochloride - capsules hard - 150 base milligrams

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency.;  ;  ; clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency. - capsule - 150 mg - active: clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency.     excipient: erythrosine gelatin indigo carmine ink lactose monohydrate magnesium stearate maize starch purified talc titanium dioxide active: clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency. excipient: gelatin ink lactose monohydrate magnesium stearate maize starch purified talc titanium dioxide - clindamycin hydrochloride has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever. 2.lower respiratory infections including bronchitis, pneumonia, emphysema and lung abscess. 3. skin and soft tissue infections including acne, furuncles, cellulitis, impetigo, abscesses, and wound infections. for specific skin and soft tissue infections like erysipelas and paronychia (panaritium), it would seem logical that these conditions would respond very well to clindamycin therapy. 4. bone and joint infections including osteomyelitis and septic arthritis. 5. pelvic infections including endometritis, cellulitis, vaginal cuff infection tubo-ovarian abscesses salpingitis and pelvic inflammatory disease when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. in cases of cervicitis due to chlamydia trachomatis, mono therapy with clindamycin has been shown to be effective in eradicating the organism. 6. intra-abdominal infections including peritonitis and abdominal abscess when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. 7. septicemia and endocarditis - the effectiveness of clindamycin in the treatment of selected cases of endocarditis has been documented when clindamycin is determined to be bactericidal to the infecting organism by in vitro testing of appropriate achievable serum concentrations. 8. dental infections such as periodental abscess and periodonitis. 9. as an alternative therapy when used in combination with quinine or amodiaquine for the treatment of multi-drug resistant plasmodium falciporum infection.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - clindamycin hydrochloride - oral capsule - 150mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin phosphate, quantity: 22.8 mg/g (equivalent: clindamycin, qty 20 mg/g) - cream - excipient ingredients: purified water; polysorbate 60; benzyl alcohol; stearic acid; cetyl esters wax; propylene glycol; liquid paraffin; sorbitan monostearate; cetostearyl alcohol - dalacin v cream 2% is indicated for the treatment of symptomatic bacterial vaginosis. note: for the purposes of this indication bacterial vaginosis is usually defined by positive results to at least three of the four following criteria: 1. vaginal discharge with ph > 4.5; 2. vaginal discharge demonstrating an amine ("fishy") odour with the addition of 10% potassium hydroxide; 3. vaginal discharge with "clue cells" on microscopy, and; 4. a gram stain consistent with a diagnosis of bacterial vaginosis (lactobacillus morphotype absent or markedly decreased; gardnerella morphotype predominant flora; white blood cells absent or few; mobiluncus morphotype may or may not be present). other pathogens which may be associated with genital infection such as trichomonas vaginalis, candida albicans, chlamydia trachomatis and neisseria gonorrhoeae should be ruled out by appropriate laboratory means.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - clindamycin hydrochloride - oral capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - clindamycin hydrochloride - oral capsule - 150mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - clindamycin hydrochloride - oral capsule - 150mg